SOURCE: OmniComm Systems, Inc.

November 28, 2007 09:30 ET

Cardium Therapeutics and Its Subsidiary, Tissue Repair Company (TRC), Extend Their Relationship With OmniComm Systems, Inc. as Their Preferred Web-Based Data Collection and Management Solution

Phase 2b Clinical Trial of Excellarate™ for Diabetic Ulcers to Use OmniComm's First in Functionality™ Electronic Data Capture (EDC) Solution, TrialMaster®

FT. LAUDERDALE, FL--(Marketwire - November 28, 2007) - OmniComm Systems, Inc. (OTCBB: OMCM), a leader in integrated electronic data capture (EDC) solutions for clinical trials, today announced that they will provide EDC services to Tissue Repair Company for a randomized, double-blind, placebo-controlled, comparator arm clinical trial to evaluate the safety and efficacy of Excellarate for the potential treatment of non-healing diabetic foot ulcers. Excellarate is a DNA-based topical gel that is being developed to stimulate wound healing. The study is currently enrolling patients diagnosed with Type I or II diabetes with a non-healing foot ulcer present that has failed standard of care therapy. The study will enroll approximately 210 patients at 25 U.S. medical clinics.

"After successful completion of a Phase 1/2 clinical trial that proved Excellarate to be safe and well tolerated and resulted in a high rate of complete wound closure, we are excited to be underway with our Phase 2b study. We believe that Excellarate has the potential to be a best-in-class product compared to currently marketed products," said Barbara Sosnowski, Vice President of Operations for Tissue Repair Company. "We chose to use EDC and specifically TrialMaster in this study for the innate benefits that EDC provides such as ease of use, better access to the data, shorter study timelines and quicker study completion."

Cardium's Tissue Repair Company (TRC) subsidiary is focused on the development of growth factor therapeutics that promote tissue repair and regeneration. TRC's lead product candidate, Excellarate is being developed as a potential treatment of non-healing diabetic foot ulcers. The Excellarate topical gel uses TRC's Gene Activated Matrix™ (GAM) technology that is designed to provide localized and sustained cellular release of platelet-derived growth factor-BB protein.

"OmniComm is very proud to be chosen by Tissue Repair Company for this important diabetic wound healing trial. It gives us great satisfaction to know that Cardium and its subsidiaries recognize TrialMaster as a superior EDC solution for their trials," said Cornelis F. Wit, CEO of OmniComm. "The fact that Cardium chose us once again for EDC for their clinical trials proves that we are delivering on our promise to provide a product that is easy to use, flexible and cost effective along with the dedicated support services that our clients need and expect."

About OmniComm

OmniComm Systems, Inc. ( provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments.

OmniComm ranked in the top 150 as one of the fastest revenue growth technology companies in North America during the last 5 years. OmniComm Systems Inc. has corporate headquarters in Ft. Lauderdale, Florida with offices in California, Maryland, New York, North Carolina and Texas.

Contact Information

    Lizanne Kelley
    OmniComm Systems, Inc.
    954-473-1254 Extension 283
    Email Contact